187 related articles for article (PubMed ID: 33313238)
1. Target therapy for metastatic alveolar soft part sarcoma: a retrospective study with 47 cases.
Liu J; Fan Z; Li S; Gao T; Xue R; Bai C; Zhang L; Tan Z; Fang Z
Ann Transl Med; 2020 Nov; 8(22):1493. PubMed ID: 33313238
[TBL] [Abstract][Full Text] [Related]
2. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.
Stacchiotti S; Mir O; Le Cesne A; Vincenzi B; Fedenko A; Maki RG; Somaiah N; Patel S; Brahmi M; Blay JY; Boye K; Sundby Hall K; Gelderblom H; Hindi N; Martin-Broto J; Kosela H; Rutkowski P; Italiano A; Duffaud F; Kobayashi E; Casali PG; Provenzano S; Kawai A
Oncologist; 2018 Jan; 23(1):62-70. PubMed ID: 28754721
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of Anlotinib in the treatment of advanced sarcoma].
Yan Q; Yao WT; Du XH; Guo LY; Fan YC
Zhonghua Zhong Liu Za Zhi; 2023 Oct; 45(10):904-910. PubMed ID: 37875427
[No Abstract] [Full Text] [Related]
4. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.
Kim M; Kim TM; Keam B; Kim YJ; Paeng JC; Moon KC; Kim DW; Heo DS
Oncologist; 2019 Jan; 24(1):20-e29. PubMed ID: 30254189
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
Liu Z; Gao S; Zhu L; Wang J; Zhang P; Li P; Zhang F; Yao W
Cancer Med; 2021 Nov; 10(21):7593-7600. PubMed ID: 34564939
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns.
Cai M; Zhu J; Zhou G
Comput Math Methods Med; 2022; 2022():3287961. PubMed ID: 35991143
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma.
Liu J; Gao T; Tan Z; Li S; Xu J; Bai C; Xue R; Xie L; Zhang L; Fan Z; Guo W
Clin Cancer Res; 2022 Aug; 28(16):3473-3479. PubMed ID: 35675031
[TBL] [Abstract][Full Text] [Related]
8. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
[TBL] [Abstract][Full Text] [Related]
9. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.
Bilici A; Koca S; Karaagac M; Aydin SG; Eraslan E; Kaplan MA; Ocak B; Goksu SS; Paydas S; Akgul F; Derin S; Ergun Y; Yekeduz E; Erol C; Ozyukseler DT; Demiray AG; Karaca M; Guc ZG; Menekse S; Cinkir HY; Gumusay O; Sakin A; Ozkul O; Demir H; Erdem D; Besiroglu M; Unal OU; Acar R; Koral L; Sahin S; Sakalar T; Bahceci A; Ozveren A; Gunaydin UM; Seker MM; Sunar V; Dal P; Artac M; Turhal S
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8243-8253. PubMed ID: 37067546
[TBL] [Abstract][Full Text] [Related]
10. Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study.
Yin J; Yin W; Zheng L; Li Y; Luo C; Zhang S; Duan L; Zhou H; Cheng K; Lang J; Xu K
Clin Med Insights Oncol; 2023; 17():11795549231175714. PubMed ID: 37435019
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
Chi Y; Fang Z; Hong X; Yao Y; Sun P; Wang G; Du F; Sun Y; Wu Q; Qu G; Wang S; Song J; Yu J; Lu Y; Zhu X; Niu X; He Z; Wang J; Yu H; Cai J
Clin Cancer Res; 2018 Nov; 24(21):5233-5238. PubMed ID: 29895706
[No Abstract] [Full Text] [Related]
12. A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer.
Shao Y; Luo Z; Yu Y; He Y; Liu C; Chen Q; Zhu F; Nie B; Liu H
Front Oncol; 2022; 12():939343. PubMed ID: 35965587
[TBL] [Abstract][Full Text] [Related]
13. Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma.
Alshamsan B; Badran A; Alshibany A; Maraiki F; Elshenawy MA; Elhassan T; Atallah JP
Cancer Manag Res; 2021; 13():6755-6766. PubMed ID: 34512015
[TBL] [Abstract][Full Text] [Related]
14. Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.
Nie C; He Y; Lv H; Gao M; Gao X; Chen B; Xu W; Wang J; Liu Y; Zhao J; Chen X
Front Oncol; 2022; 12():885350. PubMed ID: 35860585
[TBL] [Abstract][Full Text] [Related]
15. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
Liu J; Deng YT; Jiang Y
Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
[TBL] [Abstract][Full Text] [Related]
16. Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy.
Zheng A; Liu J; Liu Z; Mo Z; Fu Y; Deng Y; Jiang Y
J Cancer Res Clin Oncol; 2024 Jan; 150(2):58. PubMed ID: 38294686
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of anlotinib plus camrelizumab in treating retroperitoneal soft tissue sarcomas: a single-center retrospective cohort study.
Wu J; Li C; Liu B; Liu Q; Liu D; Wang Z; Wang X; Jia W; Tian X; Hao C
Ann Transl Med; 2023 Mar; 11(5):212. PubMed ID: 37007540
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma.
Wang HY; Chu JF; Zhang P; Wang JQ; Yan Z; Yao SN; Yao ZH; Liu YY
Onco Targets Ther; 2020; 13():1561-1568. PubMed ID: 32110053
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma.
Liu Z; Wang X; Wang J; Zhang P; Li C; Wang B; Liu G; Yao W
Front Oncol; 2022; 12():922127. PubMed ID: 35912272
[TBL] [Abstract][Full Text] [Related]
20. Alveolar soft part sarcoma: progress toward improvement in survival? A population-based study.
Fujiwara T; Nakata E; Kunisada T; Ozaki T; Kawai A
BMC Cancer; 2022 Aug; 22(1):891. PubMed ID: 35971085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
